1
Clinical Trials associated with CD70-CAR-NK cells(The Second Affiliated Hospital Zhejiang University School of Medicine) / Not yet recruitingPhase 1IIT Cord Blood-derived CD70-targeting CAR-NK Cell Therapy for Refractory/relapsed T Cell Lymphoma and Acute Myeloid Leukemia
CD70 is a promising target for immunotherapy because it is overexpressed in T-cell lymphoma (TCL) and acute myeloid leukemia (AML) tumor cells but is found in deficient levels in normal tissues and hematopoietic stem cells. This study aims to evaluate the safety and efficacy of CD70-targeted CAR-NK (CD70-CAR-NK) cells in patients with relapsed and refractory TCL and AML.
100 Clinical Results associated with CD70-CAR-NK cells(The Second Affiliated Hospital Zhejiang University School of Medicine)
100 Translational Medicine associated with CD70-CAR-NK cells(The Second Affiliated Hospital Zhejiang University School of Medicine)
100 Patents (Medical) associated with CD70-CAR-NK cells(The Second Affiliated Hospital Zhejiang University School of Medicine)
100 Deals associated with CD70-CAR-NK cells(The Second Affiliated Hospital Zhejiang University School of Medicine)